Coherus Oncology vs Ocular Therapeutix
Ocular Therapeutix is the larger business, with $52.0m of revenue in fiscal 2025 against $42.2m for Coherus Oncology (1.2 times as much). Coherus Oncology grew faster (59.8% against -18.5%). Coherus Oncology kept more of each dollar of sales as profit: a net margin of 398.4% against -511.9%. Coherus Oncology carries less debt relative to equity (0.0% against 10.9%).
| Latest fiscal year | Coherus OncologyCHRS, 2025 | Ocular TherapeutixOCUL, 2025 |
|---|---|---|
| Revenue | $42.2m | $52.0m |
| Revenue growth | 59.8% | -18.5% |
| Net income | $168m | −$266m |
| Operating margin | -429.5% | -519.8% |
| Net margin | 398.4% | -511.9% |
| Return on equity | — | -54.9% |
| Free cash flow | −$139m | −$217m |
| Cash | $88.9m | $737m |
| Total debt | $0 | $71.3m |
| Debt to equity | 0.0% | 10.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 147 | 325 |
| Market value | $116m | $1.48bn |
| Price vs our value range | — | — |
| Moat score | 19 (Weak) | 17 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 29 sales |